Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 18 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
KRITO PHARMA from Tervuren, company number BE0500718255, closed financial year 2025 with a result of € 79,606 after tax. For that financial year KRITO PHARMA recorded a gross margin of € 239,878 and equity of € 359,179. Compared with financial year 2024, the result moved from € 30,352 to € 79,606. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on October 9, 2025.
€ 359,179
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 79,606
▲ 162% vs 2024
Profit after tax over the fiscal year.
€ 36,516
▼ 9% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 78,000 paid out
98 % of the profit went to the shareholders, mostly to T.LAMOTE (100 % of the shares). That is where the money ends up.
People and assets in 2025
1.6
▼ 0.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 108,681
▼ 8% vs 2024
€ 67,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
€ 708,874
▼ 15% vs 2024
€ 134,542 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 18,699
▼ 34% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 10,514
▼ 36% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 206,626 | € 184,983 | € 208,635 | € 239,878 | ▲ 15% |
| Profit after taxes | € 50,418 | € 42,401 | € 30,352 | € 79,606 | ▲ 162% |
| Equity | € 310,820 | € 335,221 | € 357,573 | € 359,179 | |
| Total debts | € 1,872,015 | € 1,762,663 | € 1,694,525 | € 1,653,142 | ▼ 2% |
| Cash | € 85,013 | € 46,344 | € 40,225 | € 36,516 | ▼ 9% |
| Land & buildings | € 471,075 | € 452,265 | € 433,455 | € 414,645 | ▼ 4% |
| Retained profit | € 190,820 | € 215,221 | € 237,573 | € 239,179 | ▲ 1% |
| Dividend | € 40,000 | € 18,000 | € 8,000 | € 78,000 | ▲ € 70,000 |
| Bank debt | € 1,078,684 | € 957,989 | € 836,634 | € 708,874 | ▼ 15% |
| Balance sheet total | € 2,182,835 | € 2,097,884 | € 2,052,098 | € 2,012,321 | ▼ 2% |
| Employees (FTE) | 1.8 | 1.4 | 2.1 | 1.6 | ▼ 0.5 |
Key figures of KRITO PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 October 2026.
What happened to KRITO PHARMA?
What happened at KRITO PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 79,606 (▲ 162% vs 2024). Source: NBB ↗
- New establishment in Tervuren. KBO
- T. Lamote became a director. NBB
- Tervest became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 50,418 profit in 2022 to € 79,606 profit in 2025.
Paid € 24,267 in corporate taxes since 2022.
Best year ever: 2025, with € 79,606 profit.
On average € 149,900 of value added per employee in 2025.
A new publication or filing at KRITO PHARMA? We notify you, reason included.
Follow KRITO PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of T.LAMOTE, TERVEST comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
KRITO PHARMABehind KRITO PHARMA are T. Lamote and Tervest. The shares are held by T.LAMOTE (100%) and TERVEST (100%). It owns 100% of Curapharma itself.
Directors
According to the 2025 annual accounts
Director · represented by Tom Lamote
since 2012
since 2012
Participations
100%
Establishments
Establishment units
Physical locations of this company
Sterrebeeklaan 32
3080 Tervuren
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0500.718.255
- VAT number
- BE 0500.718.255
- Registered office
- Sterrebeeklaan 32, 3080 Tervuren
- Names & denominations
- KRITO PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 7 November 2012
- Peppol
- Active · Active since 17 Nov 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Activiteiten van holdings
Holdings